G Medical Innovations announces receipt of patent from USPTO for vital signs sensors
Rehovot, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
Day: February 13, 2023
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader...
Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System
Latest Swoop® software improves image quality for DWI imaging of the brainGUILFORD, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Hyperfine,...
Cannabix Technologies to Test Contactless Alcohol Breathalyzer (CAB) in Montana
Cannabix has developed a contactless alcohol breathalyzer for employers and vehicles Cannabix Contactless Alcohol Breathalyzer Contactless Alcohol Breathalyzer for workplace...
NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology
TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a...
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder...
ICU Medical Announces Time of Fourth Quarter 2022 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and...
Cerevance Expands Series B Financing with Additional $51 Million
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase...
SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering
BILLERICA, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology...
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...
Smart for Life to Hold Shareholder Meeting on March 15, 2023
Shareholder Meeting Follows the Company’s Successful Hearing with the Nasdaq Hearings PanelMIAMI, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Smart for...
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023...
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing...
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical...
SmileDirectClub Introduces CarePlus Premium Aligner Offering
New service gives customers even more choice with expanded ways to get started and manage aligner care in-person or remotelyNASHVILLE,...
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults
Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is...
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023...
The dirt on soil health: The Weston Family Soil Health Initiative awards $10 million in funding to support the adoption of soil health improving practices on Canada’s farmlands
Crops against blue sky Densely packed grain filled wheat stands against a blue sky background with scattered white cloudsTORONTO, Feb....